Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQSBX4)

Drug Name

Clazosentan Drug Info

Synonyms

Clazosentan; 180384-56-9; Ro-61-1790; VML-588; UNII-3DRR0X4728; AXV-343434; CHEMBL109648; 3DRR0X4728; Clazosentan [INN]; VML 588; AXV 034; AXV-034343; Ro 61-1790; AXV-034; AXV 034343; AC1O5FK3; SCHEMBL1652657; CTK4D7597; DTXSID60170955; ZINC3939238; BDBM50066370; AKOS032946377; SB18855; N-[6-(2-HYDROXYETHOXY)-5-(2-METHOXYPHENOXY)-2-[2-(2H-TETRAZOL-5-YL)-4-PYRIDINYL]-4-PYRIMIDINYL]-5-METHYL-2-PYRIDINESULFONAMIDE; DB-065318; FT-0765561

Indication

Disease Entry	ICD 11	Status	REF
Cerebral vasospasm	BA85.Z	Phase 3	[1]
Vasospasm	9B74.0	Discontinued in Phase 3	[2]

Cross-matching ID

PubChem CID: 6433095
CAS Number: CAS 180384-56-9
TTD Drug ID: DMQSBX4

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Endothelin A receptor (EDNRA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bosentan	DMIOGBU	Pulmonary arterial hypertension	BB01.0	Approved	[4]
Ambrisentan	DMD1QXW	Pulmonary arterial hypertension	BB01.0	Approved	[5]
Macitentan	DMP79A1	Cardiovascular disease	BA00-BE2Z	Approved	[6]
Sparsentan	DMMP51W	IgA nephropathy	MF8Y	Approved	[7]
LU302146	DMMJVXZ	Pulmonary hypertension	BB01	Approved	[8]
Atrasentan	DMM74PK	Diabetic nephropathy	GB61.Z	Phase 3	[9]
PF-1228305	DMS1EQ7	Pulmonary hypertension	BB01	Phase 3	[10]
Darusentan	DMN8DQH	Hypotension	BA20-BA21	Phase 3	[11]
BQ-123	DM0MO8I	Pulmonary arterial hypertension	BB01.0	Phase 2	[12]
FR139317	DMEL5SV	Hypertension	BA00-BA04	Phase 2	[13]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Endothelin receptor (EDNR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aprocitentan	DMEJICQ	Hypertension	BA00-BA04	Phase 2	[1]
TAK-044	DMBQ87R	Renal failure	GB60-GB6Z	Discontinued in Phase 2	[14]
Ro-46-2005	DMRT6FV	Hypertension	BA00-BA04	Terminated	[15]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Endothelin A receptor (EDNRA)	TTKRD0G	EDNRA_HUMAN	Antagonist	[3]
Endothelin receptor (EDNR)	TTCV6O0	NOUNIPROTAC	Antagonist	[1]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017374)
3	Effects of the selective endothelin A (ET(A)) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subar... Acta Neurochir (Wien). 2007;149(9):911-8; discussion 918.
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
6	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
7	Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
8	Influence of endothelin receptor antagonists on myocardial protein kinase C isoforms in uraemic cardiomyopathy. Clin Sci (Lond). 2002 Aug;103 Suppl 48:276S-279S.
9	Effects of a selective ET(A)-receptor antagonist, atrasentan (ABT-627), in murine models of allergic asthma: demonstration of mouse strain specificity. Clin Sci (Lond). 2002 Aug;103 Suppl 48:367S-370S.
10	Pfizer. Product Development Pipeline. March 31 2009.
11	Endothelin ETA receptor blockade with darusentan increases sodium and potassium excretion in aging rats. J Cardiovasc Pharmacol. 2006 Mar;47(3):456-62.
12	Endothelin in heart failure: a promising therapeutic target Heart. 1997 Feb;77(2):93-4.
13	Reduction of bFGF-induced smooth muscle cell proliferation and endothelin receptor mRNA expression by mevastatin and atorvastatin. Biochem Pharmacol. 2002 Aug 1;64(3):497-505.
14	Pharmacology of a non-selective ETA and ETB receptor antagonist, TAK-044 and the inhibition of myocardial infarct size in rats. Br J Pharmacol. 1995 Mar;114(5):949-54.
15	In vitro characterization of Ro 46-2005, a novel synthetic non-peptide endothelin antagonist of ETA and ETB receptors. FEBS Lett. 1993 Nov 15;334(2):210-4.